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Abstract
Rationale: Enhancing non–CFTR (cystic fibrosis transmembrane
conductance regulator)-mediated anion secretion is an attractive
therapeutic approach for the treatment of cystic fibrosis (CF) and
other mucoobstructive diseases.
Objectives: To determine the effects of TMEM16A potentiation on
epithelial fluid secretion and mucociliary clearance.
Methods: The effects of a novel low-molecular-weight TMEM16A
potentiator (ETX001) were evaluated in human cell and animal
models of airway epithelial function and mucus transport.
Measurements and Main Results: Potentiating the activity of
TMEM16A with ETX001 increased the Ca21-activated Cl2 channel
activity and anion secretion in human bronchial epithelial (HBE)
cells from patients with CF without impacting calcium signaling.
ETX001 rapidly increased fluid secretion and airway surface
liquid height in CF-HBE cells under both static conditions and
conditions designed to mimic the shear stress associated with tidal
breathing. In ovine models of mucus clearance (tracheal mucus
velocity and mucociliary clearance), inhaled ETX001 was able to
accelerate clearance both when CFTR function was reduced by
administration of a pharmacological blocker and when CFTR
was fully functional.
Conclusions: Enhancing the activity of TMEM16A increases
epithelial fluid secretion and enhances mucus clearance independent
of CFTR function. TMEM16A potentiation is a novel approach for
the treatment of patients with CF and non-CF mucoobstructive
diseases.
Keywords: mucus clearance; mucus hydration; anoctamin-1;
calcium-activated chloride channel
Cystic fibrosis (CF) is a recessive genetic
multiorgan disease that is primarily
associated with pulmonary, gastrointestinal,
and reproductive tract dysfunction (1). CF is
estimated to affect 75,000 patients globally
and is caused by loss of function mutations
in the anion channel, CFTR (cystic fibrosis
transmembrane conductance regulator).
Impaired CFTR function results in defective
fluid and solute transport across epithelia
with consequences for the hydration status
and pH of the mucosal environment (2, 3).
In the lungs, a major phenotype associated
with the loss of CFTR function is a
hyperconcentrated mucus gel that is poorly
removed from the airways by mucociliary
and cough clearance mechanisms (4–6),
leading to chronic bacterial infection and a
progressive loss of lung function. CFTR
modulators, which can partially rescue
the function of mutated CFTR, have
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demonstrated improved clinical outcomes
in those patients genetically suited to these
therapies and have received recent U.S.
Food and Drug Administration approval
(7). However, those patients who do not
share mutations in CFTR that are
susceptible to these drugs will require
alternative therapeutics that are mutation
independent.
CFTR-independent approaches to treat
the ion transport defect in CF include
targeting the epithelial sodium channel
(ENaC) with blockers to attenuate fluid
reabsorption from the airways and increasing
the activity of the Ca21-activated Cl2
channel (CaCC) to promote fluid secretion
(8). Before understanding the molecular
identity of the airway epithelial CaCC,
denufosol, an inhaled P2Y2-receptor agonist,
was developed as a treatment for CF lung
disease (9, 10). In vitro, the denufosol-
mediated increase in intracellular Ca21
concentration ([Ca21]i) activated the CaCC
and attenuated ENaC function in cultured
airway epithelial cells, resulting in a transient
increase in airway fluid volume (10–12). The
subsequent lack of clinical benefit of
denufosol has been ascribed to the short
pharmacodynamic activity of a compound
that depleted intracellular Ca21 stores and
desensitized the receptor. This would render
the epithelium refractory to further
stimulation by either residual denufosol or
the endogenous P2Y2-receptor ligands, ATP
and uridine-59-triphosphate (UTP) (12, 13),
potentially slowing mucus transport in the
longer term. Furthermore, a global elevation
of cellular Ca21 in the airway epithelium by
denufosol also stimulated an acute goblet cell
exocytosis (9) that may have negatively
impacted changes in lung function
subsequent to the increased volume of
mucus in the airways. The therapeutic utility
of upregulating the CaCC pathway thereby
remained an unanswered question.
In 2008, TMEM16A (anoctamin-1)
was identified as the gene encoding the
airway CaCC (14–16). Like CFTR,
TMEM16A conducts both Cl2 and HCO3
2
across the airway epithelium and is
expressed in both the surface epithelium
and submucosal glands. In contrast to
CFTR, TMEM16A is also abundantly
expressed in goblet cells and becomes
upregulated under inflammatory
conditions (14, 17). Using high-throughput
screens of compound libraries together
with medicinal chemistry optimization,
we have identified novel, selective
“potentiators” of TMEM16A. We define a
TMEM16A potentiator as a compound
that enhances the activity of the channel to
an endogenous stimulus, rather than
directly activating the channel through an
elevation of [Ca21]i, as was the case with
denufosol. Herein, we report that the
potentiation of TMEM16A channel
function using ETX001 enhances airway
epithelial anion and fluid secretion in CF
bronchial epithelial cells and promotes
mucus clearance in in vivo models of
mucociliary clearance (MCC) in sheep.
These data support the concept of positive
modulation of TMEM16A as a target for
respiratory diseases and that compounds
such as ETX001 represent therapeutic
candidates for clinical development. Some
of the results of these studies have been
previously reported in the form of
abstracts (18–20).
Methods
For full details of methods used, data
analysis, and the use of statistical tests,
please refer to the online supplement.
Cell Culture
Human bronchial epithelial (HBE) cells were
provided by Dr. Scott Randell (University of
North Carolina at Chapel Hill) from both
the University of North Carolina at Chapel
Hill and the Cystic Fibrosis Foundation
Therapeutics cell collections. A total of
eight individual donor-derived cell codes
were used that included both F508del
homozygous mutations, as well as F508del
heterozygous cells in which the second allele
was of minimal function (see online
supplement for full details). Cells were
cultured at air–liquid interface (ALI), as
previously described (21). In some studies,
HBE cells were treated with IL-13 (10
ng/ml; 48 h) to increase the TMEM16A
assay window (22). FRT-hTMEM16A cells
(Fischer rat thyroid cells stably expressing
human TMEM16Aabc) were provided
by Dr. Luis Galietta (Genoa, Italy) and
were cultured, as previously described
(14). Chinese hamster ovary cells
stably expressing full-length sheep
TMEM16A (CHO-sTMEM16A) were
obtained from SB Drug Discovery
(Glasgow, Scotland).
Whole-Cell Patch-Clamp Assay
Whole-cell voltage-clamp recordings from
FRT-hTMEM16A or CHO-sTMEM16A
were made using the QPatch planar patch-
clamp system, as described previously (23).
TMEM16A currents were assessed using
chloride-selective solutions with calculated
free [Ca21]i buffered at 260 nM, a value
measured to give 20% of full current
activation. Current rectification ratios
were calculated by dividing the
magnitude of the outward current at
190 mV by the magnitude of the inward
current at 290 mV.
Short-Circuit Current Measurements
HBE cells mounted in Ussing chambers in
symmetrical Ringer’s solutions were voltage
clamped, as previously described (21).
Following the addition of amiloride to
inhibit the ENaC-mediated short-circuit
current (ISC), the sarco/endoplasmic
reticulum Ca21-ATPase pump inhibitor
cyclopiazonic acid (CPA) or UTP was
added to the cells to elevate [Ca21]i levels to
enable the efficacy of ETX001 to be
evaluated.
Intracellular Ca21 Measurements
CF-HBE cells, cultured at ALI for 14 to 21 days
and pretreated with IL-13 (10 ng/ml; 48 h),
were loaded with the Ca21-sensitive
fluorescent reporter dye Calcium 6 (Molecular
Devices) for 120 minutes at 378C in Hanks’
balanced salt solution buffered with 20 mM
N-2-hydroxyethylpiperazine-N9-ethane
At a Glance Commentary
Scientific Knowledge on the
Subject: Although increasing anion
conductance via CFTR (cystic fibrosis
transmembrane conductance
regulator) modulation is a clinically
validated approach for treating cystic
fibrosis (CF), it is only suited to
patients with specific mutations.
What This Study Adds to the Field:
This report describes a novel positive
modulator of the calcium-activated
chloride channel, TMEM16A, which
enhances anion and fluid secretion in
epithelial cells from patients with CF
and accelerates mucociliary clearance
in vivo. This approach offers the
potential to treat all patients with CF
as both a standalone therapy and in
combination with CFTR modulators.
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sulfonic acid (pH 7.4). Calcium 6 was used
because its Kd for calcium (320 nM)
effectively covers the reported physiological
range of [Ca21]i mobilization by
purinoceptors in these cells (0.1–1 mM;
24, 25). The effects of UTP and ETX001
were then tested for direct effects on [Ca21]i
by addition to the apical surface of the
epithelia before reading in a PHERAstar
plate reader (BMG Lab Tech). Cumulative
concentration responses to UTP were also
established in the presence or absence of
ETX001 to test for the potential for the
compound to enhance a UTP-stimulated
increase in [Ca21]i.
Airway Surface Liquid Height Assay
HBE cells were washed to remove
accumulated mucus and the airway surface
liquid (ASL) was stained with Texas-Red
dextran, as previously described (23). XZ-
confocal microscopy (SP5; Leica) was used
to monitor changes in ASL height both
before and after the imposition of shear
stress (0.5 dyne/cm2) at 14 cycles per
minute to mimic tidal breathing (26). CF-
HBE cells used for these studies were not
pretreated with IL-13.
In Vivo Studies
All animal studies were approved by the
Institutional Animal Care and Use
Committee of the Mount Sinai Medical
Center (Miami, FL). Tracheal mucus
velocity (TMV) was measured in conscious
sheep that had been administered
aerosolized CFTRInh172, a CFTR blocker, to
slow the rate of TMV, as previously
described (27). Test compounds were
administered to sheep by aerosolization
into the lungs and effects on TMV were
measured. Alternatively, whole-lung MCC
was assessed in conscious sheep following
inhalation of technecium-99 (99mTc)-
labeled sulfur colloid particles (21). These
animals had not been pretreated with
CFTRInh172. Test compounds were again
administered by aerosolization but at




To identify positive modulators of
TMEM16A, parallel fluorescence and
electrophysiological screening campaigns
were used to interrogate a large (.150 K
compounds) low-molecular-weight
chemical library. After hit triage and
confirmation, a low potency primary hit
was identified that weakly enhanced
TMEM16A currents produced by 260 nM
[Ca21]i in the whole-cell patch-clamp assay
at a concentration of 30 mM (Figures 1A
and 1B). Subsequent rounds of medicinal
chemistry optimization improved potency
and efficacy and delivered ETX001.
ETX001 robustly potentiated TMEM16A
currents in both the inward and outward
directions, preserving the characteristic
biophysical properties of the channel of
outward rectification and time-dependent
activation/inactivation (14–16). However,
the outward rectification was significantly
reduced by ETX001, consistent with a more
pronounced effect on the inward (outward
chloride ion flow) than the outward
currents (inward chloride ion flow). The
rectification ratio of 20.36 4.5 in the
absence of compound was reduced to
3.76 0.2 by 3.33 mM ETX001 (n= 10;
P, 0.002). The effects of ETX001 were
concentration dependent with a half-
maximal effective concentration (EC50) of
1166 16 nM up to a maximum magnitude
of 3456 36% (n= 14) (Figures 1C–1E).
When [Ca21]i was reduced to 0 nM, below
the threshold for TMEM16A activity,
ETX001 was without effect, consistent with
its effect being channel potentiation rather
than activation (see Figure E1 in the online
supplement). Using the identical FRT-
hTMEM16A cell line cultured as a
monolayer on Snapwell inserts, ETX001
also potentiated UTP-stimulated current
changes in ion transport experiments (see
Figure E2).
Potentiation of Calcium-activated
Anion Secretory Currents in Primary
HBE Cells from Patients with CF by
ETX001
The effects of ETX001 on the anion
secretory currents in fully differentiated
HBE cells from patients with CF grown at
ALI and pretreated with IL-13 for 48 hours
was assessed in two formats of the ISC
assay. They first used a concentration
required to give 20% of the maximal effect
(EC20) of the sarco/endoplasmic reticulum
Ca21-ATPase pump inhibitor CPA to
elevate [Ca21]i, providing a stable baseline
to assess the cumulative concentration
response to ETX001. In this format,
ETX001 effectively enhanced the anion
secretory currents, an effect that was
fully inhibited by the selective TMEM16A
blocker, Ani9 (Figure 2A). The EC50 for
ETX001 was 1776 23 nM with a
2626 22% potentiation of baseline
current (n= 52 inserts from eight different
CF donor codes). Potency and efficacy
values from the primary cell assay were
found to correlate well with the
recombinant system used in the QPatch
assay for the ETX series of TMEM16A
potentiators (Figure 2C).
The second assay format assessed the
effect of ETX001 on anion currents elicited
in HBE cells using a physiologically relevant
stimulus, the P2Y2-receptor agonist UTP.
As shown in Figure 2D, ETX001 (1 mM)
significantly potentiated the magnitude of
the anion current response to increasing
concentrations of UTP, enhancing both the
peak current and the duration of the
current response as evidenced by the
residual current level at the end of each
UTP response. Integrating the area under
the curve for each addition, the potentiating
effect of ETX001 could be quantified
(Figures 2E and E4). ETX001 also
potentiated the UTP-stimulated anion
current in non–IL-13 treated CF-HBE cells
(Figures 2F and 2G).
The ion transport effect of ETX001 in
HBE cells was selective and limited to the
calcium-activated chloride conductance.
Pretreatment of HBE cells with ETX001
revealed no effects on either the amiloride-
sensitive ISC response (ENaC-dependent)
or the forskolin-stimulated anion secretion
(CFTR-dependent) (see Figure E5).
To build confidence in a direct effect
of ETX001 on TMEM16A function, we
evaluated whether there was any
impact of ETX001 on [Ca21]i in CF-
HBE cells. It has been suggested that
TMEM16A activity can regulate the levels
of [Ca21]i in epithelial cells (28) and
activation of TMEM16A can elevate
[Ca21]i. ETX001 was without effect on
the baseline levels of [Ca21]i per se
(Figure 3B), or the magnitude and
sensitivity of the response to the calcium-
mobilizing P2Y2-receptor agonist UTP
(Figures 3B and 3C).
ETX001 Increases Fluid Secretion and
ASL Height in CF-HBE Cells
To establish whether potentiation of
TMEM16A-mediated anion currents could
ultimately enhance airway fluid secretion, a
model of shear stress–induced mucosal
hydration was used (26). In this system,
ORIGINAL ARTICLE




































































Figure 1. ETX001 is a potent and efficacious potentiator of human recombinant TMEM16A (anoctamin-1). (A and C) Whole-cell patch-clamp
electrophysiological recordings from Fischer rat thyroid cells stably expressing hTMEM16A in the absence (black lines) and presence (red lines) of primary
screening hit (A) and the optimized compound ETX001 (C) at indicated concentrations. Dashed lines indicate the zero-current level. (B and D) Current–
voltage relationships for vehicle and indicated concentrations of compounds are shown. (E) Concentration–response curves for the primary screening hit
and ETX001. Mean data (6SEM) (screening hit n=5; ETX001 n=14) are shown. EC50 = half-maximal effective concentration.
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CF-HBE cells were exposed to conditions
designed to mimic the shear stress
associated with tidal breathing. These forces
stimulate the endogenous release of ATP
and adenosine, which regulate both [Ca21]i
and [cAMP]i, respectively, thereby
controlling TMEM16A and CFTR function
(29, 30) (Figure 4A). Fluid secretion could
then be quantified by measuring the change
in height of the ASL using confocal
microscopy. ETX001 (1 mM) was able to
significantly increase fluid secretion and ASL
height in CF-HBE cells from multiple
donors. Following exposure to ETX001
for 60 minutes under static conditions (no
shear stress), ASL height increased
compared with the vehicle control
(Figures 4B and 4C). The subsequent
imposition of cyclical shear stress induced
an increase in ASL height in the vehicle-
treated CF-HBE cells that was enhanced in
the ETX001-treated epithelia (Figures 4B
and 4C).
Potentiation of TMEM16A Enhances
MCC In Vivo
In vitro, ETX001 potentiated recombinant
sheep TMEM16A with an EC50 of 1276 21
nM and a magnitude of 5546 104% (n= 7;
see Figure E6). We also demonstrated the
expression of TMEM16A in primary
cultures of ovine tracheal epithelial
cells and the presence of a robust
UTP-stimulated anion secretory current in
these cells (see Figure E6). The ability of
inhaled ETX001 to affect the rate and
magnitude of mucus clearance in vivo was
assessed using two sheep models. Dosing
sheep with inhaled CFTRInh172 slowed the
rate of TMV over a 4-hour period after
administration (Figure 5A). TMV remained
attenuated for the duration of the study.
Dosing with inhaled ETX001 after
previously slowing TMV with CFTRInh172

















































































































































Figure 2. ETX001 potentiates the calcium-activated anion secretory current in primary cystic fibrosis (CF)–human bronchial epithelial (HBE) cells. (A)
Sample raw data trace illustrating the experimental protocol for assessing the effects of TMEM16A (anoctamin-1) potentiator compounds. Increasing
concentrations of ETX001 were added to CF-HBE cells following stimulation of the short-circuit current (ISC) with a submaximal (EC20) concentration of
cyclopiazonic acid (CPA). Ani9 (10 mM; downward arrow) was added at the completion of each experiment to confirm the sensitivity of the ISC response to
the TMEM16A blocker. (B) Sample concentration–response data derived from the raw data in A. (C) Correlation of data from the CPA ISC assay to the
QPatch whole-cell patch-clamp assay. ETX001 is shown as a solid red circle. (D) Sample raw data trace illustrating the effects of ETX001 (1 mM) on the
UTP-stimulated anion current response. After inhibition of the ENaC current with amiloride (10 mM), inserts were treated with either DMSO (gray dashed
trace) or 1 mM ETX001 (red line) before the cumulative addition of increasing concentrations of UTP. (E) Mean data illustrating the potentiation of the UTP
concentration response by ETX001. Data are expressed as the mean of 6 to 8 inserts of CF-HBE cells (donor: KK036H). See online supplement for
additional donor-derived CF-HBE cell data. All CF-HBE cells in A to E were IL-13 treated (10 ng/ml) for 48 hours before ion transport assay to optimize the
TMEM16A assay window. (F and G) CF-HBE cells that had not been treated with IL-13 also showed a UTP-stimulated (10 mM) anion secretory response
that was potentiated by ETX001. *P, 0.005 and **P,0.001 using a two-way ANOVA with Siadak’s multiple comparison test; #P,0.05 using two-tailed
Student’s t test. AUC=area under the curve; EC50 = half-maximal effective concentration; UTP=uridine-59-triphosphate.
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95% of the healthy baseline rate
(Figure 5A). The second model assessed
whole-lung MCC rates by measuring the
clearance of aerosolized 99mTc sulfur colloid
in naive sheep (i.e., with fully functional
CFTR). Clearance was assessed 4 hours
after inhaled dosing of either vehicle or
ETX001. As shown in Figure 5B, ETX001
gave a robust, durable, and dose-dependent
enhancement of MCC in this model.
Discussion
In this study we present data that validates
the concept that potentiating the activity of
the Ca21-activated chloride conductance
TMEM16A in airway epithelia can enhance
MCC, thus offering a novel therapeutic
approach for the treatment of patients with
CF and other diseases characterized by
mucus obstruction. Importantly, because
TMEM16A expression and function is
independent of the disease-causing
mutations in CFTR, this therapeutic
approach is predicted to be suitable for all
patients with CF (8).
The identification of low-molecular-
weight TMEM16A potentiator compounds
such as ETX001 has enabled the
physiological relevance of enhancing CaCC
activity, with respect to anion and fluid
secretion in the airway epithelium, to be
evaluated. ETX001 was identified as a potent
potentiator of TMEM16A function in a
patch-clamp assay using recombinantly
expressed TMEM16A (Figure 1). The
pharmacology of ETX001 translated from
the whole-cell electrophysiology format into
epithelial ion transport studies using either
the same FRT-hTMEM16A cell line (see
Figure E2) or CF-HBE cells (Figure 2). The
correlation between the patch-clamp and the
CF-HBE cell ion transport assays that was
observed with more than 50 compounds
from the ETX001 series (Figure 2C) builds
confidence that the Ca21-dependent
chloride secretory current in the native CF
cells is dominated by a TMEM16A-mediated
mechanism. This contrasts to a report that
TMEM16A plays only a minor role in
airway CaCC function (31). This study
suggested that only a minor component of
the CF-HBE cell CaCC-mediated response
was sensitive to the TMEM16A inhibitor,
T16A(inh)-A01. The reason for this
inconsistency is likely due to only a partial
inhibition of TMEM16A by T16A(inh)-A01
in patch-clamp studies (unpublished
observations), as well as questions
relating to the real target of this
compound (32). In terms of selectivity
versus other ion channels expressed
in the airway epithelium, ETX001 was
without effect on either CFTR-mediated
secretory responses in non–CF-HBE
cells or on ENaC-mediated currents. In
HBE cells, both CFTR and ENaC currents
depend on accessory ion channels and
transporters (e.g., NKCC1, ATP1A1,
and Kv1.7) to maintain ion transport
function (33), which are presumably
likewise unaffected by ETX001 treatment at
pharmacologically relevant concentrations.
Having established that ETX001 and
related compounds could potentiate
TMEM16A function under conditions in
which [Ca21]i was predicted to be static
(i.e., buffered at 260 nM in patch-clamp or
stable following stimulation with an EC20
concentration of CPA in CF-HBE cells), it
was important to establish whether the
pharmacology was observed over a
physiologically relevant range of [Ca21]i.
To address this, the P2Y2-receptor agonist
UTP was added to IL-13 pretreated CF-
HBE cells at increasing concentrations in
the presence or absence of ETX001. ETX001
enhanced the exogenous UTP-induced
secretory current response of CF-HBE cells
(Figure 2D), causing both a leftward shift in
the UTP concentration response and
enhancing the maximum efficacy (see
Figure 2E and additional donors in Figure
E4), consistent with the ability of ETX001 to
potentiate TMEM16A function across a
physiologically relevant range of [Ca21]i.
In these studies, CF-HBE cells had been
pretreated with IL-13 to increase the
expression and function of TMEM16A and
thereby maximize the assay window (17).
The upregulation of TMEM16A function by
IL-4 and IL-13 has been proposed to be a
regulatory mechanism to ensure that mucin
and fluid production by the airway remain
in balance and the present data therefore
support a potentiator activity of ETX001
under these inflammatory conditions.
However, the potentiator activity of ETX001
was independent of an inflamed
environment because efficacy was also
observed in IL-13–naive CF-HBE cells
(Figures 2F and 2G).
The use of P2Y2-receptor ligands in
these studies is particularly relevant because
the local release of ATP and UTP into the
airway mucosa represents a key regulatory
mechanism in the control of ion transport
and fluid homeostasis (29, 30) (Figure 4).
The release of these mediators is a kinetic
process that is stimulated by shear and
compressive forces during normal
breathing (26, 34, 35) and is proposed to
HBEs grown @
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Figure 3. ETX001 does not affect calcium handling in differentiated cystic fibrosis–human bronchial
epithelial (HBE) cells. (A) A cartoon illustrating the experimental protocol for assessing effects
of compounds on [Ca21]i in air–liquid interface cultures of HBE cells. (B and C) ETX001 (1 mM)
had no direct effect on [Ca21]i levels (B) and also had no effect on the UTP-stimulated increase in
[Ca21]i (C). Mean data6SD (n=6 inserts per group) are shown from a single donor.
addn/incubn=addition/incubation; ALI =air–liquid interface; AM=acetoxymethyl ester; RFU= relative
fluorescence units; UTP=uridine-59-triphosphate.
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adapt to maintain mucosal hydration as the
respiration rate changes following the
impaction of inhaled particulates on the
epithelium and during cough (36, 37). Tarran
and colleagues (26) illustrated that imposing
cyclical shear stress to CF-HBE cells to mimic
tidal breathing induced an ATP-dependent
increase in fluid secretion, measured as an
increase in height of ASL. Using a similar
model system, ETX001 enhanced the
fluid secretory response of CF-HBE cells
(Figure 4). The ETX001-enhanced increase in
fluid secretion was observed both before
and after the initiation of shear stress, further
supporting the conclusion that potentiation
of TMEM16A could be achieved over the
range of resting to physiologically stimulated
[Ca21]i.
Two in vivo sheep models were used
to evaluate the potential for ETX001 to
increase mucus clearance. Inhaled dosing of
ETX001 to conscious sheep enhanced the
rates of airway mucus clearance in the
CFTR-inhibited TMV model (27) and in
the whole-lung clearance model in which
CFTR function is normal (21). Nominal
doses in the range of 30 to 100 mg/kg
provided a long-lasting enhancement of
mucus clearance in both models. The
efficacy observed in the whole-lung MCC
model in which CFTR function is normal
provides early data to support the concept
that a TMEM16A potentiator may show
benefit in patients with CF who are treated
with CFTR potentiator and corrector
therapies, as well as in patients without CF
who have alternative mucoobstructive lung
disease.
To our knowledge, this is the first
report of the discovery and efficacy of
TMEM16A potentiator compounds.
Compounds initially reported to be direct
modulators of the channel (e.g., Eact) (38)
have subsequently been shown to act
indirectly via elevation of [Ca21]i (39, 40),
negating their utility for validating CaCC
function due to the numerous other cellular
effects elevation of [Ca21]i will trigger
(e.g., goblet cell exocytosis and
bronchospasm). In contrast, ETX001
potentiates the opening of the TMEM16A
channel (i.e., it enhances the magnitude of
the current in the presence of physiologically
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Figure 4. ETX001 enhances fluid secretion in cystic fibrosis–human bronchial epithelial (HBE) cells under static and shear stress–stimulated conditions.
(A) A cartoon illustrating the physiological regulation of anion secretion in the human airway epithelium. (B) Sample XZ confocal images of airway surface
liquid (ASL) visualized using Texas red staining in the absence and presence of ETX001 (1 mM). (C) The change in ASL height from baseline was measured
following a 1-hour treatment with ETX001 or vehicle under static conditions (i.e., no shear stress) and after 3 hours of continual shear stress. Data are
expressed as the mean change in ASL height (6SEM) for seven to eight inserts from a F508del/F508del HBE cells donor and is representative of three
independent experiments. Cystic fibrosis–HBE cells had not been pretreated with IL-13. *P,0.001 and **P,0.00001 for ETX001-treated versus time-
matched vehicle control using two-tailed Student’s t test. TMEM16A=anoctamin-1.
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cause increases in [Ca21]i per se. This
conclusion is supported by two pieces of
data. First, ETX001 enhances current in
whole-cell patch-clamp studies when
[Ca21]i is clamped and heavily buffered with
a combination of both fast (BAPTA) and
slow (EGTA) chelators. Second, ETX001 was
shown to have no effect on [Ca21]i levels in
fully differentiated CF-HBE cells per se nor
any effect on the response to a calcium-
mobilizing agonist, UTP (Figure 3). These
findings are in contrast to others that have
suggested positive TMEM16A modulation
will lead to increases in [Ca21]i, albeit those
studies have used extrapolations from
knockdown approaches and nonselective
compounds that are proposed to be
TMEM16A blockers (28). It has recently
been suggested that inhibiting the function of
TMEM16A may be of therapeutic benefit for
the treatment of CF (41). This proposal is
based on reports that nonselective regulators
of TMEM16A function may have effects on
airway smooth muscle and mucin release
from goblet cells (42, 43). To date, we have
observed no effects of TMEM16A potentiator
compounds on airway smooth muscle
function (in vitro) or lung function (in vivo)
(unpublished observations). Likewise, there
were no effects of ETX001 or related
compounds on the central to peripheral
ratios of 99mTc in the lung scans from the
sheep MCC model, changes that would have
been expected were there a bronchospasm
associated with TMEM16A potentiator
administration (unpublished observations).
Selective potentiators and blockers of
TMEM16A will enable a thorough evaluation
of the physiological role of this channel in a
variety of biological systems.
Conclusions
The concept that enhancing airway anion
secretion will provide clinical benefit to
many patients with CF is now well
established with CFTR potentiator and
corrector therapies (1). Whether clinical
efficacy can be established by enhancing the
anion secretory function of TMEM16A in
the airways remains to be established. The
positive effects of ETX001 on both airway
fluid secretion in CF-HBE cells and mucus
clearance in vivo, together with the
population of patients with CF who are not
genetically matched to existing CFTR repair
therapies, build a case for testing the
hypothesis in the clinic. n
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